Kerala Ayurveda Limited has drawn up a plan to take Kerala’s traditional Ayurvedic treatments and products further into global markets. The company has put forward a long-term strategy titled Vision 2030, aiming to scale its revenue to ₹1,000 crore by 2030.
As one of the rare Kerala-based Ayurvedic companies listed on the stock market, Kerala Ayurveda is trying to position itself for faster growth. The plan, according to the company, leans heavily on research, product development and a broader network of treatment centres. The company also hints that stronger international presence—especially in Europe and the US—could play a major role in lifting revenue over the next few years.
The second quarter of the financial year 2025-26, covering July–September, saw the company slip into a consolidated loss of ₹6.35 crore. The same quarter last year had shown a smaller loss of ₹4.01 crore.
This drop follows a profitable first quarter (April–June), when the company earned ₹2.02 crore. The shift back to losses appears linked to the rise in expenses tied to expansion. With the company aggressively widening its footprint, costs seem to have picked up faster than revenue.
Despite the loss, revenue during the July–September quarter rose 17.7% to ₹36.54 crore, compared with ₹31.05 crore a year earlier. The June quarter was slightly higher at ₹38 crore.
Across the first six months of the financial year, the company generated ₹74.62 crore—an increase of 27% over the previous year. Kerala Ayurveda expects to close the current financial year with ₹160 crore in revenue, implying a growth of around 30%. This appears dependent on steady demand and continued traction in international markets.
A major factor behind the revenue jump has been the strong performance of the company’s e-commerce business within India. This segment grew by more than 50%, while its direct-to-consumer sales through its own website tripled compared with the first half of the previous year.
International operations also added momentum. The wellness centre business in the US recorded an 82% rise, and new clinics in Singapore contributed additional support. These shifts suggest that global consumers may be showing more interest in Ayurvedic wellness, though the long-term trend remains to be seen.
Kerala Ayurveda released its second-quarter results on November 18. The stock, which had closed with a gain of nearly 2% the previous trading session, inched up slightly after the announcement.
Over the past year, the shares have delivered a 37% return to investors. However, so far this year, the stock has fallen 11%. The company also has the backing of well-known value investor Porinju Veliyam, which often draws attention from market watchers.